{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:58:08Z","timestamp":1779307088941,"version":"3.51.4"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:p>Isocitrate dehydrogenase (IDH) mutations have been recognized in a few neoplasms including glioma, acute myeloid leukemia, chondrosarcoma, cholangiocarcinoma, and angioimmunoblastic T-cell lymphoma. The direct methods to detect IDH mutations include DNA sequencing, immunohistochemistry (IHC), or by measuring its byproduct, 2-hydroxyglutarate (2-HG), in the blood or urine. Moreover, conventional magnetic resonance imaging can be modified to magnetic resonance spectroscopy (MRS) to measure 2-HG in tumor. By conducting a search in Medline\/PubMed and ISI\/Web of Science for the published articles in English related to the methods for detection of IDH mutations and its byproduct 2-HG, we compared different methodologies to detect these mutations and discuss advantages and limitations of each method. Studies in which a methodology of detection was compared with another modality were included. Multiple studies have shown that both DNA sequencing and IHC are reliable methods for detecting IDH mutations in glioma and other solid neoplasms. IHC appeared to be less costly, easier to perform, and may be slightly more accurate than DNA sequencing. 2-HG has also been measured in bone marrow aspirate, serum and urine of patients with mutant IDH acute myeloid leukemia, and correlated very well with sequencing and IHC. Lastly, in some glioma patients, MRS detected IDH mutations noninvasively and reliably with excellent correlations with other modalities such as IHC and sequencing. In conclusion, IHC, MRS, and 2-HG detection all are clinically useful and comparable with DNA sequencing in identifying IDH mutations in different neoplasms. 2-HG and MRS can be utilized for monitoring treatment response in a variety of neoplasms.<\/jats:p>","DOI":"10.1097\/pai.0000000000000342","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T18:09:24Z","timestamp":1457201364000},"page":"334-337","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms"],"prefix":"10.1097","volume":"25","author":[{"given":"Shahab","family":"Babakoohi","sequence":"first","affiliation":[{"name":"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, School of Medicine, Baltimore, MD"},{"name":"Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rena G.","family":"Lapidus","sequence":"additional","affiliation":[{"name":"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[{"name":"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Sausville","sequence":"additional","affiliation":[{"name":"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashkan","family":"Emadi","sequence":"additional","affiliation":[{"name":"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231121","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discov"},{"key":"R2-20231121","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1101\/gad.217406.113","article-title":"What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer","volume":"27","author":"Losman","year":"2013","journal-title":"Genes Dev"},{"key":"R3-20231121","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"R4-20231121","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"R5-20231121","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.exphem.2013.12.001","article-title":"Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations","volume":"42","author":"Emadi","year":"2014","journal-title":"Exp Hematol"},{"key":"R6-20231121","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.bbrc.2011.02.102","article-title":"Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation","volume":"406","author":"Kaneko","year":"2011","journal-title":"Bioch Biophys Res Commun"},{"key":"R7-20231121","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11060-011-0596-3","article-title":"IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors","volume":"105","author":"Mellai","year":"2011","journal-title":"J Neurooncol"},{"key":"R8-20231121","first-page":"2058","article-title":"Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas","volume":"40","author":"Loussouarn","year":"2012","journal-title":"Int I Oncol"},{"key":"R9-20231121","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/NEN.0b013e31822713f0","article-title":"Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens","volume":"70","author":"Preusser","year":"2011","journal-title":"J Neuropathol Exp Neurol"},{"key":"R10-20231121","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1593\/tlo.12424","article-title":"2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping","volume":"6","author":"Esmaeili","year":"2013","journal-title":"Transl Oncol"},{"key":"R11-20231121","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1182\/blood-2012-06-438267","article-title":"Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response","volume":"120","author":"Fathi","year":"2012","journal-title":"Blood"},{"key":"R12-20231121","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1750-3639.2009.00327.x","article-title":"PCR- and restriction endonuclease-based detection of IDH1 mutations","volume":"20","author":"Meyer","year":"2010","journal-title":"Brain Pathol"},{"key":"R13-20231121","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1309\/AJCPZOIY3WY4KIKE","article-title":"IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance","volume":"138","author":"Thota","year":"2012","journal-title":"Am J Clini Pathol"},{"key":"R14-20231121","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jmoldx.2011.06.004","article-title":"Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis","volume":"13","author":"Patel","year":"2011","journal-title":"J Mol Diagn: JMD"},{"key":"R15-20231121","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/neuonc\/not015","article-title":"Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing","volume":"15","author":"Agarwal","year":"2013","journal-title":"Neuro Oncol"},{"key":"R16-20231121","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1750-3639.2009.00352.x","article-title":"Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors","volume":"20","author":"Capper","year":"2010","journal-title":"Brain Pathol"},{"key":"R17-20231121","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10014-011-0023-7","article-title":"Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing","volume":"28","author":"Takano","year":"2011","journal-title":"Brain Tumor Pathol"},{"key":"R18-20231121","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbrc.2013.02.049","article-title":"A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation","volume":"432","author":"Kato","year":"2013","journal-title":"Biochemical Biophys Res Commun"},{"key":"R19-20231121","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbrc.2013.01.088","article-title":"Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations","volume":"432","author":"Kaneko","year":"2013","journal-title":"Biochemical Biophys Res Commun"},{"key":"R20-20231121","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1620\/tjem.230.103","article-title":"Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations","volume":"230","author":"Kato Kaneko","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"R21-20231121","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00401-010-0647-4","article-title":"Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing","volume":"119","author":"Felsberg","year":"2010","journal-title":"Acta Neuropathol"},{"key":"R22-20231121","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-013-1056-z","article-title":"Interlaboratory comparison of IDH mutation detection","volume":"112","author":"van den Bent","year":"2013","journal-title":"J Neurooncol"},{"key":"R23-20231121","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2013-03-493197","article-title":"Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia","volume":"121","author":"DiNardo","year":"2013","journal-title":"Blood"},{"key":"R24-20231121","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer cell"},{"key":"R25-20231121","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ijc.26425","article-title":"2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1\/2 mutation status or tumor size","volume":"131","author":"Capper","year":"2012","journal-title":"Int J Cancer"},{"key":"R26-20231121","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat Med"},{"key":"R27-20231121","doi-asserted-by":"crossref","first-page":"116ra4","DOI":"10.1126\/scitranslmed.3002693","article-title":"Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy","volume":"4","author":"Andronesi","year":"2012","journal-title":"Sci Transl Med"},{"key":"R28-20231121","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11060-011-0737-8","article-title":"Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy","volume":"107","author":"Pope","year":"2012","journal-title":"J Neurooncol"},{"key":"R29-20231121","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/ml300225h","article-title":"Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo","volume":"3","author":"Popovici-Muller","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"R30-20231121","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/1471-2164-13-341","article-title":"A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers","volume":"13","author":"Quail","year":"2012","journal-title":"BMC Genomics"},{"key":"R31-20231121","doi-asserted-by":"crossref","first-page":"e30087","DOI":"10.1371\/journal.pone.0030087","article-title":"Direct comparisons of Illumina vs. Roche 454 sequencing technologies on the same microbial community DNA sample","volume":"7","author":"Luo","year":"2012","journal-title":"PLoS One"},{"key":"R32-20231121","doi-asserted-by":"crossref","first-page":"e19534","DOI":"10.1371\/journal.pone.0019534","article-title":"Comparison of sequence reads obtained from three next-generation sequencing platforms","volume":"6","author":"Suzuki","year":"2011","journal-title":"PLoS One"},{"key":"R33-20231121","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The definition of primary and secondary glioblastoma","volume":"19","author":"Ohgaki","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R34-20231121","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1231677","article-title":"(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible","volume":"339","author":"Losman","year":"2013","journal-title":"Science"}],"container-title":["Applied Immunohistochemistry &amp; Molecular Morphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00129039-201705000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:36:27Z","timestamp":1700580987000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00129039-201705000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/pai.0000000000000342","relation":{},"ISSN":["1541-2016"],"issn-type":[{"value":"1541-2016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}